Latest filing published 05 Aug 2026 for Rocket Pharmaceuticals, INC.. Read the official filing
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
David P. Southwell is a declared insider at 3 companies (chief executive); the most frequent names are PTC Therapeutics, Inc., Rocket Pharmaceuticals, Inc. and TScan Therapeutics, Inc. We count 18 filings; the first trade dates from 8 September 2021 and the latest from 3 August 2026.
On the market, this insider has only ever bought: 2 purchases, €133k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 7 share grants and 6 option exercises.
The latest filing, published on 5 August 2026, reports a transaction in Rocket Pharmaceuticals, Inc. The clock since the last published purchase (20 May 2022) now reads 1,612 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations